MESO Key Statistics, Chart & Performance
The current stock price of MESO is 18.03 USD. In the past month the price increased by 10.62%. In the past year, price increased by 54.86%.
MESO Latest News, Press Relases and Analysis
MESO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.54B | ||
| AMGN | AMGEN INC | 15.17 | 178.66B | ||
| GILD | GILEAD SCIENCES INC | 14.81 | 150.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.25 | 115.62B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.01 | 75.74B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 896.2 | 60.38B | ||
| INSM | INSMED INC | N/A | 43.81B | ||
| NTRA | NATERA INC | N/A | 33.65B | ||
| BIIB | BIOGEN INC | 10.88 | 26.73B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.4 | 20.91B | ||
| INCY | INCYTE CORP | 16.13 | 20.33B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.20B |
Related stock screener links
About MESO
Company Profile
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. The company is headquartered in Melbourne, Victoria and currently employs 81 full-time employees. The company went IPO on 2004-12-16. The company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. The company is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. The company has established commercial partnerships in Europe and China for certain Phase III assets.
Company Info
MESOBLAST LTD- SPON ADR
L 38 55 Collins St
Melbourne VICTORIA 3000 AU
CEO: Silviu Itescu
Employees: 73
Phone: 61396396036
MESOBLAST LTD- SPON ADR / MESO FAQ
What does MESOBLAST LTD- SPON ADR do?
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. The company is headquartered in Melbourne, Victoria and currently employs 81 full-time employees. The company went IPO on 2004-12-16. The company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. The company is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. The company has established commercial partnerships in Europe and China for certain Phase III assets.
What is the stock price of MESOBLAST LTD- SPON ADR today?
The current stock price of MESO is 18.03 USD. The price increased by 4.89% in the last trading session.
What is the dividend status of MESOBLAST LTD- SPON ADR?
MESO does not pay a dividend.
What is the ChartMill technical and fundamental rating of MESO stock?
MESO has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting MESO stock to perform?
10 analysts have analysed MESO and the average price target is 15.83 USD. This implies a price decrease of -12.19% is expected in the next year compared to the current price of 18.03.
What sector and industry does MESOBLAST LTD- SPON ADR belong to?
MESOBLAST LTD- SPON ADR (MESO) operates in the Health Care sector and the Biotechnology industry.
Can you provide the number of employees for MESOBLAST LTD- SPON ADR?
MESOBLAST LTD- SPON ADR (MESO) currently has 73 employees.
MESO Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to MESO. When comparing the yearly performance of all stocks, MESO is one of the better performing stocks in the market, outperforming 90.83% of all stocks.
MESO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MESO. MESO has a bad profitability rating. Also its financial health evaluation is rather negative.
MESO Financial Highlights
Over the last trailing twelve months MESO reported a non-GAAP Earnings per Share(EPS) of -0.84. The EPS increased by 5.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.02% | ||
| ROE | -17.1% | ||
| Debt/Equity | 0.12 |
MESO Forecast & Estimates
10 analysts have analysed MESO and the average price target is 15.83 USD. This implies a price decrease of -12.19% is expected in the next year compared to the current price of 18.03.
For the next year, analysts expect an EPS growth of 54.99% and a revenue growth 431.05% for MESO